‘Efficacy will lead’ as first-line JAK inhibitor use picks up in moderate to severe UC
Despite a class-wide black box warning for prescribing in the early setting, 31% of providers reported positioning Janus kinase inhibitors as first-line treatment among patients with severe ulcerative colitis, according to survey results. “Where it is positioned in the label today is after an anti-TNF, meaning that patients had to have been on some form of TNF […]
First ever MASH drug primed for big impact in USA
Research suggests there will likely be strong uptake for the first USA-approved therapy for metabolic dysfunction-associated steatohepatitis (MASH). Madrigal Pharmaceuticals (Nasdaq: MDGL) recently scored a US Food and Drug Administration (FDA) nod for Rezdiffra (resmetirom) as a treatment for MASH, alongside diet and exercise. As the first prescription medicine for a large treatment opportunity, Rezdiffra has the […]
Docs sing praises of Madrigal’s Rezdiffra, predict rapid uptake
Madrigal Pharmaceuticals already has physicians singing from its hymn sheet. Shortly after the biotech won approval in metabolic dysfunction-associated steatohepatitis (MASH), most gastroenterologists said they were familiar with its drug and planning to trial the brand within six months of its launch. Spherix Global Insights captured the views in a survey that asked 81 gastroenterologists for their […]
As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model
Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” for the field, the drug—dubbed Cyltezo—has struggled to gain traction thanks to the surprising resilience of AbbVie’s autoimmune blockbuster. Now, in the face of lackluster Cytelzo sales, Boehringer has decided to prune its ranks in the U.S. and adopt […]
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Excitement grows as the FDA’s first approval for MASH treatment nears commercialization, according to Spherix Global Insights. Exton, PA., April 5, 2024 – As the first treatment to gain FDA approval for metabolic dysfunction-associated steatohepatitis (MASH), Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) is poised to make a sizable impact on a condition with substantial unmet need. As […]
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market
Takeda’s line extension has outpaced other concurrent launches in adoption and familiarity three months post launch, according to Spherix Global Insights. Exton, PA., March 22, 2024 – The end of 2023 introduced several new treatment options for patients suffering from ulcerative colitis (UC). Among them is Eli Lilly’s Omvoh (mirikizumab), the first FDA approved IL-23 […]
When it Comes to Treating Ulcerative Colitis, US Gastroenterologists May be Betting it All on JAK…
Spherix Global Insights find JAK inhibitors, led by AbbVie’s Rinvoq, establishing significant footholds in both first and later line UC treatment. [Exton PA, November 30, 2023] – With the Ulcerative Colitis (UC) market set to heat up in the coming months, the JAK class seems poised to become a dominant treatment, challenging established alternative mechanism […]
US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lilly’s Omvoh, Pfizer’s Velsipity, Takeda’s Subcutaneous Entyvio, and Celltrion’s Zymfentra
Prior to launch, prescribers estimate that TNF inhibitors are likely to bear the greatest brunt of increased adoption of the newest market entrants, according to Spherix Global Insights [Exton PA, November 13, 2023] — In the past two months, the landscape of available treatments for ulcerative colitis (UC) has undergone a significant expansion, marked by […]
Amgen’s Amjevita Remains the Frontrunner in the US Adalimumab Biosimilars Market, Despite Increased Competition, According to Spherix Global Insights.
Boehringer Ingelheim’s Cyltezo has a slight competitive edge over other concurrent biosimilar launches on certain key performance metrics, though prescriber future projections show little differentiation in use among the recent entrants. Exton, PA, September 14, 2023 — This summer ushered in the highly anticipated introduction of a multitude of additional adalimumab biosimilars to the dynamic […]
An Old Dog with a New Trick… Ellodi’s APT-1011 Promises EoE Patients a Convenient and Potent Treatment Alternative
Spherix Global Insights finds doctors have yet to define where APT-1011 will sit in the treatment path relative to EoE treatment gold standard, Dupixent. Exton, PA., August 15, 2023 – Since launching in May 2022, Sanofi/Regeneron’s Dupixent has been well received by gastroenterologists and allergists as an advancement for treating eosinophilic esophagitis (EoE). More than […]
